Toggle Main Menu Toggle Search

ePrints

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation

Lookup NU author(s): Dr Matthias Schmid, Dr Brendan Payne

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2016 British HIV Association. Objectives: No randomized controlled trials have yet reported an individual patient benefit of initiating combination antiretroviral therapy (cART) at CD4 counts > 350 cells/μL. It is hypothesized that earlier initiation of cART in asymptomatic and otherwise healthy individuals may lead to poorer adherence and subsequently higher rates of resistance development. Methods: In a large cohort of HIV-positive individuals, we investigated the emergence of new resistance mutations upon virological treatment failure according to the CD4 count at the initiation of cART. Results: Of 7918 included individuals, 6514 (82.3%), 996 (12.6%) and 408 (5.2%) started cART with a CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Virological rebound occurred while on cART in 488 (7.5%), 46 (4.6%) and 30 (7.4%) with a baseline CD4 count ≤ 350, 351-499 and ≥ 500 cells/μL, respectively. Only four (13.0%) individuals with a baseline CD4 count > 350 cells/μL in receipt of a resistance test at viral load rebound were found to have developed new resistance mutations. This compared to 107 (41.2%) of those with virological failure who had initiated cART with a CD4 count < 350 cells/μL. Conclusions: We found no evidence of increased rates of resistance development when cART was initiated at CD4 counts above 350 cells/μL. HIV Medicine


Publication metadata

Author(s): Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S, Fisher M, Gazzard B, Gilson R, Gompels M, Hay P, Johnson M, Kegg S, Leen C, Martin F, Nelson M, Palfreeman A, Post F, Pritchard J, Sachikonye M, Schwenk A, Tariq A, Walsh J, Hill T, Jose S, Phillips A, Sabin C, Thornton A, Dunn D, Glabay A, Fisher M, Perry N, Tilbury S, Youssef E, Churchill D, Gazzard B, Nelson M, Everett R, Asboe D, Mandalia S, Post F, Korat H, Taylor C, Gleisner Z, Ibrahim F, Campbell L, Gilson R, Brima N, Williams I, Johnson M, Youle M, Lampe F, Smith C, Tsintas R, Chaloner C, Hutchinson S, Phillips A, Hill T, Thornton A, Huntington S, Walsh J, Mackie N, Winston A, Weber J, Ramzan F, Carder M, Orkin C, Lynch J, Hand J, de Souza C, Anderson J, Munshi S, Ainsworth J, Schwenk A, Miller S, Wood C, Leen C, Wilson A, Morris S, Gompels M, Allan S, Palfreeman A, Memon K, Lewszuk A, Chadwick D, Cope E, Gibson J, Kegg S, Main P, Mitchell, Hunter, Hay P, Dhillon M, Martin F, Russell-Sharpe S, Allan S, Harte A, Clay S, Tariq A, Spencer H, Jones R, Pritchard J, Cumming S, Atkinson C, Delpech V, Sachikony M, Aitken C, Asboe D, Pozniak A, Cane P, Chadwick D, Churchill D, Clark D, Collins S, Delpech V, Douthwaite S, Fearnhill E, Porter K, Tostevin A, White E, Fraser C, Geretti AM, Hale A, Hue S, Kaye S, Kellam P, Lazarus L, Leigh-Brown A, Mbisa T, Mackie N, Moses S, Orkin C, Nastouli E, Pillay D, Smit E, Templeton K, Tilston P, Webster D, Williams I, Zhang H, Greatorex J, O'Shea S, Mullen J, Cox A, Tandy R, Fawcett T, Hopkins M, Ashton L, Booth C, Garcia-Diaz A, Shepherd J, Schmid ML, Payne B, Pereira S, Hubb J, Kirk S, Gunson R, Bradley-Stewart A

Publication type: Article

Publication status: Published

Journal: HIV Medicine

Year: 2016

Volume: 17

Issue: 5

Pages: 368-372

Print publication date: 01/05/2016

Online publication date: 25/08/2015

Acceptance date: 01/07/2015

ISSN (print): 1464-2662

ISSN (electronic): 1468-1293

Publisher: Blackwell Publishing Ltd

URL: http://dx.doi.org/10.1111/hiv.12302

DOI: 10.1111/hiv.12302


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share